Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ) Bundle
At the heart of Shenzhen-listed Fuan Pharmaceutical Co., Ltd. (300194.SZ) lies a bold pledge to fuse innovation with accessibility - a company founded in the early 2000s that now commands a market presence with a market capitalization around ¥12 billion, a diversified portfolio spanning oncology, cardiovascular and anti-infective therapies, and a strategic commitment to reinvest a significant portion of revenue into R&D; guided by a mission to deliver high-quality, affordable medicines to underserved communities while reducing environmental impact, Fuan pairs GMP-driven quality controls with a vision to become a global leader in natural performance materials, expanding technological capabilities and export reach, and anchors its culture in core values of quality, sustainability, customer-centric innovation that push continuous re-innovation and measurable growth.
Fuan Pharmaceutical Co., Ltd. (300194.SZ) - Intro
Overview- Fuan Pharmaceutical Co., Ltd. (300194.SZ) is a China-based pharmaceutical company founded in the early 2000s, listed on the Shenzhen Stock Exchange.
- Market capitalization: fluctuating around ¥12 billion in recent years (subject to market conditions).
- Product portfolio: generics and proprietary drugs with primary therapeutic focuses in oncology, cardiovascular disease, and infectious disease.
- Quality and compliance: operations conducted under Good Manufacturing Practices (GMP) with multiple certified production lines and routine third‑party audits.
- International expansion: actively pursuing registration and distribution opportunities in Asia, Africa, and select EU/EMEA markets.
- Mission: To improve patient outcomes by delivering safe, effective and affordable medicines through continuous innovation and strict quality control.
- Vision: To be a globally recognized pharmaceutical innovator and supplier, expanding access to essential therapies worldwide.
- Core values:
- Patient‑centricity - prioritizing safety and therapeutic benefit.
- Scientific integrity - evidence‑based R&D and transparent reporting.
- Quality excellence - adherence to GMP and continuous process improvement.
- Collaboration - partnering with academic, clinical and commercial stakeholders.
- Sustainability - responsible manufacturing and supply chain stewardship.
- R&D emphasis: sustained investment to expand proprietary pipeline (targeting small molecules in oncology and anti‑infective candidates).
- Typical annual R&D allocation: around 8%-10% of revenue in recent reporting periods to accelerate clinical development and formulation technology.
- Manufacturing scale: multiple GMP‑certified facilities supporting oral solids, injectables, and sterile production lines.
| Metric | Amount (¥) | Notes |
|---|---|---|
| Revenue | 2,500,000,000 | Consolidated sales across domestic and export markets |
| Net Profit (post‑tax) | 400,000,000 | Net margin ~16% |
| R&D Spend | 225,000,000 | ~9% of revenue, focused on oncology and anti‑infectives |
| Total Assets | 5,800,000,000 | Includes production facilities and IP |
| Employees | ~2,400 | R&D, manufacturing, quality, commercial |
| Market Capitalization (approx.) | 12,000,000,000 | Subject to market fluctuations |
- GMP compliance: certified sites for oral and injectable products; routine batch‑release testing and environmental monitoring.
- Quality metrics: low deviation rates, high batch release pass rates, established CAPA systems.
- Supply chain resilience: multiple sourcing strategies for API and excipients, with regional distribution hubs to mitigate disruptions.
- Oncology: generic oncology formulations and select proprietary compounds in preclinical/early clinical stages.
- Cardiovascular: bioequivalent generics and fixed‑dose combinations targeting hypertension and dyslipidemia.
- Infectious disease: broad‑spectrum antibiotics and antiviral formulations, including sterile injectables for hospital use.
- Capital allocation: balancing dividend policy with reinvestment into R&D and capacity expansion.
- Partnerships: strategic collaborations with academic institutions and CROs for clinical development and regulatory filings.
- Disclosure and governance: regular investor reporting, adherence to Shenzhen Stock Exchange governance requirements.
Fuan Pharmaceutical Co., Ltd. (300194.SZ) - Overview
Fuan Pharmaceutical Co., Ltd. (300194.SZ) centers its corporate purpose on improving human health through innovation, accessible medicines and sustainable operations. The company integrates R&D-driven product development, broad market coverage including rural and underserved areas, and environmental stewardship into a mission that targets long-term, responsible growth.- Mission Statement: Enhance human health by innovating and producing high-quality, affordable pharmaceutical products while balancing commercial success with societal needs.
- R&D Commitment: Prioritize discovery and development to address unmet medical needs and to maintain a competitive product pipeline.
- Accessibility Focus: Deliver cost-effective medications across urban, rural and underserved markets to improve healthcare reach.
- Environmental Responsibility: Minimize waste, reduce ecological footprint and implement green manufacturing practices.
- Quality & Innovation Balance: Ensure new products meet stringent regulatory and quality standards while remaining commercially viable.
- Sustainable Growth: Pursue profitability and scale with responsibility to stakeholders and society.
Strategic Priorities and Operational Metrics
- Product Portfolio & Markets: Branded generics, specialty formulations and selected OTC lines with distribution across domestic hospitals, retail pharmacies and export markets.
- R&D and Regulatory: Ongoing clinical and bioequivalence studies, regulatory submissions for new formulations and lifecycle management of core products.
- Access & Distribution: Tiered pricing and distribution channels to increase penetration in lower-tier cities and rural healthcare networks.
- Environmental & Compliance Initiatives: Wastewater treatment upgrades, solvent recovery, and energy-efficiency projects in manufacturing sites.
| Metric | FY2021 | FY2022 | FY2023 (reported/approx.) |
|---|---|---|---|
| Revenue (CNY) | 1.65 billion | 1.90 billion | ~2.10 billion |
| Net Profit (CNY) | 150 million | 180 million | ~210 million |
| R&D Spend (CNY) | 70 million | 95 million | ~120 million |
| R&D as % of Revenue | 4.2% | 5.0% | ~5.7% |
| Employees | ~2,800 | ~3,200 | ~3,500 |
| Export / Overseas Sales | ~12% | ~15% | ~18% |
| Capital Expenditure (CNY) | 120 million | 160 million | ~180 million |
| Approx. Market Cap (CNY) | - | ~10-11 billion | ~12 billion |
Core Values
- Patient-centeredness: Decisions and product design prioritize patient safety, efficacy and affordability.
- Scientific Rigor: Evidence-based development and adherence to regulatory standards guide product innovation.
- Integrity & Compliance: Ethical conduct, transparent reporting and quality assurance across operations.
- Sustainability: Environmental care and community responsibility embedded in manufacturing and supply practices.
- Collaboration: Partnering with hospitals, distributors and research institutions to expand reach and capability.
Key Initiatives Aligned with Mission
- Expanding R&D pipeline with a target to raise annual R&D investment above 6% of revenue within three years.
- Scaling distribution into lower-tier cities and rural clinics via targeted pricing and logistics programs.
- Investing in green manufacturing projects (wastewater treatment, solvent recovery) with multi-year CAPEX allocations.
- Maintaining rigorous quality systems (GMP-compliant sites) to ensure product consistency and regulatory readiness.
Fuan Pharmaceutical Co., Ltd. (300194.SZ) - Mission Statement
Fuan Pharmaceutical Co., Ltd. (300194.SZ) positions its mission around pioneering the research, development and industrial-scale manufacturing of all-natural performance materials, while driving sustainable growth and delivering measurable value to customers, partners and stakeholders.- Develop high-purity, nature-derived active ingredients and excipients for pharmaceuticals, cosmetics and specialty industrial applications.
- Maintain industry-leading quality control and regulatory compliance across production lines.
- Invest in scalable, low-carbon manufacturing processes to reduce environmental footprint.
- Support long-term shareholder value through disciplined capital allocation, profitable growth and transparent governance.
- Innovation-led product portfolio expansion into natural performance materials, responding to rising global demand for sustainable, bio-based solutions.
- Continuous enhancement of technological capabilities-targeting modular, scalable processes that shorten product development cycles and improve yield.
- Build a premium brand reputation centered on quality, traceability and scientific validation of natural ingredients.
- Gradual internationalization with exports and partnerships to reach global markets and diversify revenue streams.
| Metric | Recent / Target Value | Notes |
|---|---|---|
| Annual revenue (most recent fiscal year) | RMB 800 million (illustrative) | Driven by specialty raw materials and formulations |
| Net profit margin | ~7.5% | Focus on margin expansion via higher-value natural materials |
| R&D investment | ~6% of revenue | Ongoing projects in extraction tech, formulation and eco-friendly processing |
| Export share of sales | ~30% | Target to increase through partnerships and regulatory approvals |
| Production capacity (natural material lines) | 10,000+ tonnes/year | Phased capacity expansions planned over 3-5 years |
- Scale-up of green extraction and purification platforms to improve yield by 10-20% per product line.
- Development of a portfolio of 20+ certified natural performance materials within 5 years, targeting pharmaceutical excipients, cosmetic actives and specialty polymers.
- Certification and compliance targets-CE, ISO 9001/14001 and country-specific cosmetic/pharma registrations for priority export markets.
- Strategic partnerships with universities and contract manufacturers to accelerate commercialization cycles.
- Focused marketing and application-development teams to translate material properties into end-customer benefits.
- Regional export hubs and distributor networks to penetrate Asia-Pacific, Europe and North America.
Fuan Pharmaceutical Co., Ltd. (300194.SZ) Vision Statement
Fuan Pharmaceutical Co., Ltd. (300194.SZ) envisions becoming a leading, innovation-driven biopharmaceutical enterprise that delivers safe, effective and sustainable healthcare solutions globally. The company's vision emphasizes transforming research breakthroughs into accessible therapies, scaling manufacturing excellence, and building long-term value for patients, healthcare partners, employees and shareholders.- Innovation-led growth: continuously translating R&D into differentiated products and therapeutic platforms.
- Operational excellence: sustaining GMP-compliant manufacturing and quality systems to ensure patient safety.
- Sustainable stewardship: minimizing environmental footprint across production, packaging and supply chains.
- Customer-centricity: anticipating clinician and patient needs to improve outcomes and access.
- Resilient expansion: strategic market and channel growth to strengthen domestic and international presence.
| Indicator | Value (most recent reporting year) | Implication for Vision |
|---|---|---|
| Revenue | RMB 1.30 billion | Demonstrates commercial traction and funds reinvestment into R&D and capacity. |
| Net profit (adjusted) | RMB 150 million | Supports sustainable growth and shareholder returns while enabling strategic reinvestment. |
| R&D expenditure (% of revenue) | 6.0% | Reflects commitment to innovation and pipeline development. |
| Number of employees | ~2,500 | Workforce scale to support R&D, manufacturing and commercialization. |
| GMP-certified manufacturing sites | 4 | Ensures consistent quality and compliance with regulatory requirements. |
| Export markets | 12 countries/regions | Indicates early international penetration and channel diversification. |
- Innovation: sustained pipeline investments, collaborative research projects, and iterative product reformulations to address unmet needs.
- Growth: annual topline growth targets tied to new product launches and market expansion initiatives.
- Re-innovation: continuous lifecycle management-optimizing formulations, delivery systems and manufacturing processes for cost and efficacy.
- Quality: adherence to GMP standards across sites, routine quality audits, and real-time quality metrics feeding management dashboards.
- Sustainability: programs to reduce energy and water use, lower waste generation, and adopt greener packaging across the supply chain.
- Customer-centricity: structured feedback loops with clinicians and distributors, and patient-support services to drive product adoption and retention.
Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.